Última actualización 6 de julio de 2026
Key finding
Trabecular thickness was significantly higher in the dapagliflozin group (0.230 ± 0.02 vs 0.218 ± 0.01, p=0.003).
This study investigated the effects of dapagliflozin on bone metabolism in post-menopausal women with type 2 diabetes, finding significant improvements in trabecular and cortical thickness.
Quick read
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Long-Term (1–5 y)
Risk of bias
Some Concerns
Guarda este estudio en tu Evidence Tracker para encontrarlo facilmente cuando lo necesites.
Plain-language summary
A plain-language read of the study's main message and where it applies.
Study focus
This study investigated the effects of dapagliflozin on bone metabolism in post-menopausal women with type 2 diabetes, finding significant improvements in trabecular and cortical thickness.
Understanding the impact of dapagliflozin on bone metabolism is crucial for managing the health of post-menopausal women with type 2 diabetes, a group at increased risk for osteoporosis. The findings suggest that dapagliflozin may offer additional benefits beyond glucose control, potentially improving bone health and reducing fracture risk in this population.
The study did not measure long-term effects on fracture risk. Sample size and demographic characteristics may limit generalizability. The study design does not allow for causal conclusions.
Published in
Publication details and source links for this paper.
Sanjay KB, Liza D, Mintu B, et al. Effects of Dapagliflozin on Bone Metabolism in Post-Menopausal Women with Type 2 Diabetes. Journal of the Endocrine Society. 2024;8(Suppl 1):bvae163.370. doi:10.1210/jendso/bvae163.370
Trabecular thickness was significantly higher in the dapagliflozin group (0.230 ± 0.02 vs 0.218 ± 0.01, p=0.003).
Cortical thickness was significantly higher in the dapagliflozin group (1.104 ± 0.2 vs 0.998 ± 0.2, p=0.04).
Intra-cortical porosity was significantly higher in the dapagliflozin group (0.008 ± 0.005 vs 0.005 ± 0.003, p=0.020).
Evidence network
Understand where this research contributes within the broader evidence network.
This study contributes evidence to Dapagliflozin and Bone mineral density (BMD), Bone mineral density (BMD) at distal radius, Bone mineral density (BMD) at femoral neck, and 7 more.
This study contributes evidence to
Primary intervention
Dapagliflozin
Primary outcomes
Evidence topics
Primary intervention
Intervention and outcome relationships this study adds to the evidence network.
Editorial context
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
2
Related topics
10
Evidence pairs
22
Related studies
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Guarda estudios y paginas de evidencia, organiza tu Evidence Tracker y manten en un solo lugar la investigacion que te importa.
Evidencia principal
Relación de evidencia
Evidencia relacionada
Relación de evidencia
Seguir evidencia
Tema de evidencia
Seguir evidencia
Core evidence
The primary outcomes reported in this study.
Dapagliflozin → Bone mineral density (BMD)
Dapagliflozin → Bone mineral density (BMD)
Dapagliflozin → Bone mineral density (BMD) at distal radius
Dapagliflozin → Bone mineral density (BMD) at distal radius
Dapagliflozin → Bone mineral density (BMD) at femoral neck
Dapagliflozin → Bone mineral density (BMD) at femoral neck
Dapagliflozin → Cortical pore diameter (Ct.Po.Dm) at radius
Dapagliflozin → Cortical pore diameter (Ct.Po.Dm) at radius
Dapagliflozin → Cortical pore diameter (Ct.Po.Dm) at tibia
Dapagliflozin → Cortical pore diameter (Ct.Po.Dm) at tibia
Dapagliflozin → Cortical thickness (Co.Th)
Dapagliflozin → Cortical thickness (Co.Th)
Dapagliflozin → Intra-cortical porosity (Ct.Po)
Dapagliflozin → Intra-cortical porosity (Ct.Po)
Dapagliflozin → Trabecular thickness (Tb.Th)
Dapagliflozin → Trabecular thickness (Tb.Th)
Create a free account to save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.
Today's Activity
Saved this study
Your free account becomes your personal diabetes evidence workspace.
Evidence Tracker
12 tracked topics
Saved Studies
48 studies
Research Notes
Coming Soon
Weekly Evidence Digest
Coming Soon
Keep this study in your Evidence Tracker so you can easily find it again whenever you need it.
Today's Activity
Saved this study
Your free account becomes your personal diabetes evidence workspace.
Evidence Tracker
12 tracked topics
Saved Studies
48 studies
Research Notes
Coming Soon
Weekly Evidence Digest
Coming Soon
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on SGLT2 Inhibitors and Bone Mineral Density, SGLT2 Inhibitors and Bone Mineral Density.
This study contributes to the evidence on the following intervention-outcome relationships.
Medications
Medications
Curated evidence collections and hubs this study is part of.
All studies measuring Bone Mineral Density
Measures Bone Mineral Density as a key outcome.
All studies on SGLT2 Inhibitors
Contributes to SGLT2 Inhibitors evidence base.
Latest published studies
Published within the last 2 years.
Jump to pre-filtered views in the evidence archive.
1 results
1 results
1 results
1 results
1 results
Generated from the study's connected evidence using Evidence Intelligence™.
SGLT2 Inhibitors may improve Kidney Function.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
Serum CTX-1
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on 6 supporting studies with consistent results and a positive effect signal.
Limitations
Current evidence does not show a clear benefit of SGLT2 Inhibitors for Bone Mineral Density.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Bone mineral density (BMD)
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Bone mineral density (BMD) at distal radius
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Bone mineral density (BMD) at femoral neck
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Dapagliflozin appears to improve Cortical pore diameter (Ct.Po.Dm) at radius.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Cortical pore diameter (Ct.Po.Dm) at radius
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Dapagliflozin appears to improve Cortical pore diameter (Ct.Po.Dm) at tibia.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Cortical pore diameter (Ct.Po.Dm) at tibia
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Next steps
Choose a next path through related evidence topics, archive views, and research summaries.
Follow the topics this study contributes to.
Open broader archive views for this relationship.
Read related research summaries.
Focused on evidence, not advertising.
Your data is always protected.
New studies added every day.